Provider Communication for Cancer Risk Gene Testing
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if healthcare providers directly communicating genetic test results to family members of cancer patients can enhance genetic counseling and testing among those at risk. Approximately 15% of people with cancer have inherited gene changes that increase their risk, but many remain unaware due to the limited reach of genetic counseling. The study compares usual care, where patients inform their at-risk relatives, with an approach called Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients, where healthcare providers also contact the relatives. This trial suits individuals who have undergone genetic testing at City of Hope, have a known inherited cancer gene change, and have two or more first-degree relatives in the U.S. who have not yet been tested. As an unphased trial, this study offers a unique opportunity to contribute to innovative approaches in genetic counseling and testing.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your healthcare provider.
What prior data suggests that provider-mediated communication is safe for improving genetic counseling and testing rates?
Research shows that when healthcare providers share genetic test results, family members at risk for cancer can better understand their risk and take action. This trial tests a communication method, not a new drug or treatment, so there are no direct safety risks involved.
Previous studies found that direct contact from healthcare providers to at-risk family members can be helpful. These studies examined the effectiveness of this method and reported no safety concerns, as it primarily involves sharing information. Therefore, potential participants can feel reassured that the safety risk is very low, given the nature of the study.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores new ways to communicate genetic testing results to families at risk for cancer. Unlike the usual approach, where patients receive a letter and test report to share with relatives, this trial includes a method where healthcare providers also directly contact relatives to discuss the results. This provider-mediated contact could improve understanding and encourage proactive health decisions among family members. The hope is that this approach will lead to better communication and ultimately help at-risk relatives make more informed choices about their health.
What evidence suggests that provider-mediated communication is effective for improving genetic counseling and testing rates?
This trial will compare two methods for communicating genetic testing results to at-risk relatives of cancer patients. Research has shown that direct communication from healthcare providers leads more relatives to undergo genetic testing. Specifically, about 64.9% of relatives got tested when contacted by a healthcare provider, compared to 54.4% when family members relayed the information. Studies have found that healthcare providers sharing results boosts relatives' confidence and understanding, resulting in more frequent genetic counseling. This approach helps more people learn about their risk and receive necessary care.14567
Who Is on the Research Team?
Stacy W. Gray
Principal Investigator
City of Hope Medical Center
Are You a Good Fit for This Trial?
This trial is for English-speaking adults in the U.S. who have a known harmful gene change linked to cancer, seen by COH Genetics, and are willing to share contact info of their relatives. Relatives must also be adults in the U.S., fluent in English, and not previously tested for this genetic variant.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive a family letter and genomic test report to share with at-risk relatives. In Arm II, relatives also receive provider-mediated contact to discuss genetic results.
Follow-up
Participants are monitored for the uptake of cascade testing among at-risk relatives and the psychosocial impact of provider-mediated contact.
What Are the Treatments Tested in This Trial?
Interventions
- Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients
Find a Clinic Near You
Who Is Running the Clinical Trial?
City of Hope Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator